158 related articles for article (PubMed ID: 28895868)
1. Identification of novel biomarkers for treatment monitoring in canine leishmaniosis by high-resolution quantitative proteomic analysis.
Martinez-Subiela S; Horvatic A; Escribano D; Pardo-Marin L; Kocaturk M; Mrljak V; Burchmore R; Ceron JJ; Yilmaz Z
Vet Immunol Immunopathol; 2017 Sep; 191():60-67. PubMed ID: 28895868
[TBL] [Abstract][Full Text] [Related]
2. Serum apolipoprotein-A1 as a possible biomarker for monitoring treatment of canine leishmaniosis.
Escribano D; Tvarijonaviciute A; Kocaturk M; Cerón JJ; Pardo-Marín L; Torrecillas A; Yilmaz Z; Martínez-Subiela S
Comp Immunol Microbiol Infect Dis; 2016 Dec; 49():82-87. PubMed ID: 27865270
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of various biomarkers for kidney monitoring during canine leishmaniosis treatment.
Pardo-Marín L; Martínez-Subiela S; Pastor J; Tvarijonaviciute A; Garcia-Martinez JD; Segarra S; Cerón JJ
BMC Vet Res; 2017 Jan; 13(1):31. PubMed ID: 28114941
[TBL] [Abstract][Full Text] [Related]
4. Changes in serum anti-Leishmania antibody concentrations measured by time-resolved immunofluorometric assays in dogs with leishmaniosis after treatment.
Cantos-Barreda A; Escribano D; Martínez-Subiela S; Pardo-Marín L; Segarra S; Cerón JJ
Vet Immunol Immunopathol; 2018 Apr; 198():65-69. PubMed ID: 29571520
[TBL] [Abstract][Full Text] [Related]
5. Changes in serum biomarkers of oxidative stress after treatment for canine leishmaniosis in sick dogs.
Rubio CP; Martinez-Subiela S; Tvarijonaviciute A; Hernández-Ruiz J; Pardo-Marin L; Segarra S; Ceron JJ
Comp Immunol Microbiol Infect Dis; 2016 Dec; 49():51-57. PubMed ID: 27865264
[TBL] [Abstract][Full Text] [Related]
6. Thyroid function in 36 dogs with leishmaniosis due to Leishmania infantum before and during treatment with allopurinol with or without meglumine antimonate.
Saridomichelakis MN; Xenoulis PG; Chatzis MK; Kasabalis D; Steiner JM; Suchodolski JS; Petanides T
Vet Parasitol; 2013 Oct; 197(1-2):22-8. PubMed ID: 23685064
[TBL] [Abstract][Full Text] [Related]
7. Monitoring the reverse to normal of clinico-pathological findings and the disease free interval time using four different treatment protocols for canine leishmaniosis in an endemic area.
Paradies P; Sasanelli M; Amato ME; Greco B; De Palo P; Lubas G
Res Vet Sci; 2012 Oct; 93(2):843-7. PubMed ID: 22296941
[TBL] [Abstract][Full Text] [Related]
8. Serum concentrations of acute-phase proteins in dogs with leishmaniosis during short-term treatment.
Martínez-Subiela S; Bernal LJ; Cerón JJ
Am J Vet Res; 2003 Aug; 64(8):1021-6. PubMed ID: 12926596
[TBL] [Abstract][Full Text] [Related]
9. Some remarks about the LeishVet directions for the treatment of canine leishmaniasis.
Lamothe J
Vet Parasitol; 2010 May; 169(3-4):416-7; author reply 418-20. PubMed ID: 20106598
[No Abstract] [Full Text] [Related]
10. Changes in saliva of dogs with canine leishmaniosis: A proteomic approach.
Franco-Martínez L; Tvarijonaviciute A; Horvatić A; Guillemin N; Bernal LJ; Barić Rafaj R; Cerón JJ; Thomas MDC; López MC; Tecles F; Martínez-Subiela S; Mrljak V
Vet Parasitol; 2019 Aug; 272():44-52. PubMed ID: 31395204
[TBL] [Abstract][Full Text] [Related]
11. TLR-2 and TLR-4 transcriptions in unstimulated blood from dogs with leishmaniosis due to Leishmania infantum at the time of diagnosis and during follow-up treatment.
Montserrat-Sangrà S; Alborch L; Ordeix L; Solano-Gallego L
Vet Parasitol; 2016 Sep; 228():172-179. PubMed ID: 27692322
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.
Manna L; Corso R; Galiero G; Cerrone A; Muzj P; Gravino AE
Parasit Vectors; 2015 May; 8():289. PubMed ID: 26017164
[TBL] [Abstract][Full Text] [Related]
13. Renal dialysis and long-term treatment of a dog with kidney disease associated with canine leishmaniosis.
Baneth G; Segev G; Mazaki-Tovi M; Chen H; Kuzi S
Parasit Vectors; 2018 Mar; 11(1):151. PubMed ID: 29554974
[TBL] [Abstract][Full Text] [Related]
14. Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinol.
Torres M; Bardagí M; Roura X; Zanna G; Ravera I; Ferrer L
Vet J; 2011 Jun; 188(3):346-51. PubMed ID: 20594876
[TBL] [Abstract][Full Text] [Related]
15. Hair parasite load as a new biomarker for monitoring treatment response in canine leishmaniasis.
Corpas-López V; Merino-Espinosa G; Acedo-Sánchez C; Díaz-Sáez V; Morillas-Márquez F; Martín-Sánchez J
Vet Parasitol; 2016 Jun; 223():20-5. PubMed ID: 27198771
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of two different drug combinations for the treatment of canine leishmaniasis.
Pennisi MG; Lo Giudice S; Masucci M; De Majo M; Reale S; Vitale F
Vet Res Commun; 2008 Sep; 32 Suppl 1():S303-5. PubMed ID: 18683068
[No Abstract] [Full Text] [Related]
17. Effect of two treatments on changes in serum acute phase protein concentrations in dogs with clinical leishmaniosis.
Daza González MA; Fragío Arnold C; Fermín Rodríguez M; Checa R; Montoya A; Portero Fuentes M; Rupérez Noguer C; Martínez Subiela S; Cerón JJ; Miró G
Vet J; 2019 Mar; 245():22-28. PubMed ID: 30819422
[TBL] [Abstract][Full Text] [Related]
18. Paraoxonase activity as a tool for clinical monitoring of dogs treated for canine leishmaniasis.
Rossi G; Ibba F; Meazzi S; Giordano A; Paltrinieri S
Vet J; 2014 Jan; 199(1):143-9. PubMed ID: 24188864
[TBL] [Abstract][Full Text] [Related]
19. PCR follow-up examination after treatment of canine leishmaniosis (CaL).
Steuber S; Moritz A; Schirrmann I; Greiner M
Tokai J Exp Clin Med; 1998 Dec; 23(6):285-92. PubMed ID: 10622624
[TBL] [Abstract][Full Text] [Related]
20. The effects of prednisone on haemostasis in leishmaniotic dogs treated with meglumine antimoniate and allopurinol.
Cortese L; Pelagalli A; Piantedosi D; Mastellone V; Di Loria A; Lombardi P; Ciaramella P; Avallone L
Vet J; 2008 Sep; 177(3):405-10. PubMed ID: 17629526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
